MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement

On July 23, 2024, MiNK received notice from NASDAQ confirming that the Company has satisfied the MVLS requirement as set forth in Nasdaq Listing Rule 5550(b)(2). Accordingly, the Company now satisfies the MVLS requirement for continued listing on the NASDAQ Capital Market and the matter is now closed. Investor Contact Media Contact NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinicalstage biopharmaceutical company pioneering the discovery, development, and commercial ...